QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
NASDAQ:PRLD

Prelude Therapeutics (PRLD) Stock Price, News & Analysis

$4.17
-0.02 (-0.48%)
(As of 02/28/2024 ET)
Today's Range
$4.05
$4.25
50-Day Range
$2.68
$4.63
52-Week Range
$1.66
$8.56
Volume
55,375 shs
Average Volume
85,894 shs
Market Capitalization
$229.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67

Prelude Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
11.9% Upside
$4.67 Price Target
Short Interest
Healthy
1.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of Prelude Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.88) to ($1.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.15 out of 5 stars

Medical Sector

748th out of 959 stocks

Pharmaceutical Preparations Industry

339th out of 437 stocks


PRLD stock logo

About Prelude Therapeutics Stock (NASDAQ:PRLD)

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

PRLD Stock Price History

PRLD Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Prelude Therapeutics Incorporated Registered Shs
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Q3 2023 Abcellera Biologics Inc Earnings Call
The Latest Analyst Ratings for Prelude Therapeutics
See More Headlines
Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
2/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRLD
Fax
N/A
Employees
128
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.67
High Stock Price Target
$5.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+11.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-121,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.32 per share

Miscellaneous

Free Float
11,237,000
Market Cap
$229.02 million
Optionable
Optionable
Beta
1.38
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Krishna Vaddi D.V.M. (Age 58)
    Ph.D., Founder, CEO & Director
    Comp: $805.91k
  • Dr. Edna Huang M.D. (Age 51)
    President & Chief Medical Officer
    Comp: $563.55k
  • Dr. Peggy A. Scherle Ph.D. (Age 63)
    Chief Scientific Officer
    Comp: $868.62k
  • Mr. Laurent Chardonnet M.B.A. (Age 59)
    Chief Financial Officer
  • Ms. Aimee Crombie Ph.D.
    Senior VP and Head of Strategic Planning & Operations
  • Dr. Madhu Pudipeddi Ph.D.
    Senior Vice President of Technical Operations
  • Lindsey Trickett
    Vice President of Investor Relations
  • Mr. Bryant David Lim J.D. (Age 53)
    Chief Legal Officer & Corporate Secretary
  • Ms. Michele Porreca M.B.A.
    Chief People Officer
  • Dr. Andrew P. Combs Ph.D. (Age 58)
    Executive VP & Head of Chemistry
    Comp: $562.46k














PRLD Stock Analysis - Frequently Asked Questions

Should I buy or sell Prelude Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" PRLD shares.
View PRLD analyst ratings
or view top-rated stocks.

What is Prelude Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 12 month price targets for Prelude Therapeutics' stock. Their PRLD share price targets range from $4.00 to $5.00. On average, they predict the company's share price to reach $4.67 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price.
View analysts price targets for PRLD
or view top-rated stocks among Wall Street analysts.

How have PRLD shares performed in 2024?

Prelude Therapeutics' stock was trading at $4.27 at the start of the year. Since then, PRLD stock has decreased by 2.3% and is now trading at $4.17.
View the best growth stocks for 2024 here
.

When is Prelude Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PRLD earnings forecast
.

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) issued its earnings results on Friday, November, 12th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.03.

When did Prelude Therapeutics IPO?

(PRLD) raised $149 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

Who are Prelude Therapeutics' major shareholders?

Prelude Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Boxer Capital LLC (4.68%), Price T Rowe Associates Inc. MD (1.90%), Price T Rowe Associates Inc. MD (1.90%), Vanguard Group Inc. (1.84%), Bridgeway Capital Management LLC (0.27%) and Pale Fire Capital SE (0.12%). Insiders that own company stock include Andrew Combs, Brian Piper, Christopher Pierce, David J Mauro, David J Mauro, Deborah Morosini, Jane Huang, Krishna Vaddi, Laurent Chardonnet, Orbimed Advisors Llc and Peggy Scherle.
View institutional ownership trends
.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRLD) was last updated on 2/28/2024 by MarketBeat.com Staff